Disufenton (Cerovive) for acute ischaemic stroke - horizon scanning review
NHSC
Record ID 32004000890
English
Authors' objectives:
This study aims to summarise the currently available evidence on disufenton (Cerovive) for acute ischaemic stroke.
Authors' recommendations:
Disufenton sodium (Cerovive, NXY-059), a nitrone with free radical trapping properties is a new treatment for acute ischaemic stroke currently in phase III trial. Treatment in trials is by intravenous infusion over 72 hours started within 6 hours of onset of symptoms. It is unknown whether there is a requirement for computed tomography (CT) scanning prior to disufenton sodium therapy.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Stroke
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.